Non-overt disseminated intravascular coagulation scoring for critically ill patients: The impact of antithrombin levels

Thrombosis and Haemostasis

Volumn 101, Issue 4, 2009, Pages 696-705

  Egi, Moritoki ^a   Morimatsu, Hiroshi ^a   Wiedermann, Christian J ^b   Tani, Makiko ^a   Kanazawa, Tomoyuki ^a   Suzuki, Satoshi ^a   Matsusaki, Takashi ^a   Shimizu, Kazuyoshi ^a   Toda, Yuichiro ^a   Iwasaki, Tatsuo ^a   Morita, Kiyoshi ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b CENTRAL HOSPITAL OF BOLZANO   (Italy)

Author keywords

Antithrombin; Disseminated intravascular coagulation; International Society on Thrombosis and Haemostasis; Predictability; Validation

Indexed keywords

ANTITHROMBIN;

ADULT; ARTICLE; BLOOD CLOTTING; COMPARATIVE STUDY; CONTROLLED STUDY; CRITICAL ILLNESS; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; SCREENING;

ADULT; AGED; ALGORITHMS; ANTITHROMBINS; BIOLOGICAL MARKERS; CRITICAL ILLNESS; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; JAPAN; LOGISTIC MODELS; MALE; MIDDLE AGED; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTHROMBIN TIME; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 64849097798     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-07-0448     Document Type: Article

References (30)

1. Levi M, Te n Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-592.
2. Muller-Berghaus G, ten Cate H, Levi M. Disseminated intravascular coagulation: clinical spectrum and established as well as new diagnostic approaches. Thromb Haemost 1999; 82: 706-712.
3. ten Cate H, Timmerman JJ, Levi M. The pathophysiology of disseminated intravascular coagulation. Thromb Haemost 1999; 82: 713-717.
4. Levi M, de Jonge E, van der Poll T, et al. Disseminated intravascular coagulation. Thromb Haemost 1999; 82: 695-705.
5. Taylor FB, Jr., Toh CH, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86: 1327-1330.
6. Wada H, Gabazza EC, Asakura H, et al. Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society on Thrombosis and Haemostasis and of the Japanese Ministry of Health and Welfare for overt DIC. Am J Hematol 2003; 74: 17-22.
7. Bernard GR, Vincent JL, Laterre P F, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
8. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. J Am Med Assoc 2001; 286: 1869-1878.
9. Hoffmann JN, Wiedermann CJ, Juers M, et al. Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thromb Haemost 2006; 95: 850-856.
10. Wiedermann CJ, Hoffmann JN, Juers M, et al. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 2006; 34: 285-292.
11. Afshari A, Wetterslev J, Brok J, et al. Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis. Br Med J 2007; 335: 1248-1251.
12. Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007; 5: 31-41.
13. Toh CH, Downey C. Performance and prognostic importance of a new clinical and laboratory scoring system for identifying non-overt disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2005; 16: 69-74.
14. Toh CH, Hoots WK. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview. J Thromb Haemost 2007; 5: 604-606.
15. Knaus WA, Draper EA, Wagner D P, et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-829.
16. National Association of Testing Authorities. Available from: http://www.nata.asn.au/
17. Hayakawa M, Gando S, Hoshino H. A prospective comparative study of three sets of criteria for disseminated intravascular coagulation: ISTH criteria vs Japanese criteria. Clin Appl Thromb Hemost 2007; 13: 65-72.
18. Hayakawa M, Gando S, Hoshino H. A Prospective comparison of new Japanese criteria for disseminated intravascular coagulation: new Japanese criteria versus ISTH criteria. Clin Appl Thromb Hemost 2007; 13: 172-181.
19. Kienast J, Juers M, Wiedermann CJ, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006; 4: 90-97.
20. Sakr Y, Reinhart K, Hagel S, et al. Antithrombin levels, morbidity, and mortality in a surgical intensive care unit. Anesth Analg 2007; 105: 715-723.
21. Ranucci M, Frigiola A, Menicanti L, et al. Postoperative antithrombin levels and outcome in cardiac operations. Crit Care Med 2005; 33: 355-360.
22. Mesters RM, Mannucci PM, Coppola R, et al. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 1996; 88: 881-886.
23. Aibiki M, Fukuoka N, Nishiyama T, et al. Differences in antithrombin III activities by administration method in critical patients with disseminated intravascular coagulation: a pharmacokinetic study. Shock 2007; 28: 141-147.
24. Asakura H, Ontachi Y, Mizutani T, et al. Decreased plasma activity of antithrombin or protein C is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation. Eur J Haematol 2001; 67: 170-175.
25. Rodeghiero F, Mannucci PM, Vigano S, et al. Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia. Blood 1984; 63: 965-969.
26. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-874.
27. Gando S, Iba T, Eguchi Y, et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 2006; 34: 625-631.
28. Gando S, Wada H, Asakura H, et al. Evaluation of new Japanese diagnostic criteria for disseminated intravascular coagulation in critically ill patients. Clin Appl Thromb Hemost 2005; 11: 71-76.
29. Le Gall JR, Klar J, Lemeshow S, et al. The Logistic Organ Dysfunction system. A new way to assess organ dysfunction in the intensive care unit. ICU Scoring Group. J Am Med ASsoc 1996; 276: 802-810.
30. Angstwurm M W, Dempfle CE, Spannagl M. New disseminated intravascular coagulation score: A useful tool to predict mortality in comparison with Acute Physiology and Chronic Health Evaluation II and Logistic Organ Dysfunction scores. Crit Care Med 2006; 34: 314-320.